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Diethylstilbestrol (DES) is a synthetic oestrogen, and its anticancer effects are exerted in androgen-dependent prostate cancer. The
administration of DES decreases serum testosterone to castration levels. However, in androgen-independent prostate cancer
patients, who are already orchiectomised, the administration of DES improves symptoms and decreases prostate-specific antigen
(PSA). The mechanisms responsible for these direct inhibitory effects have been explained as biological actions not mediated by
oestrogen receptors. We assessed the gene expression profiles of prostate cancer cells treated with DES, and investigated direct
inhibitory effects of DES. DES inhibited the proliferation of LNCaP and PC-3 cells. cDNA microarray analysis showed that expression
of many genes was downregulated by DES. However, insulin-like growth factor binding protein 6 (IGFBP-6) gene expression levels
were upregulated in PC-3 cells. IGFBP-6 gene expression and protein levels significantly increased after DES treatment. Recombinant
IGFBP-6 inhibited cell proliferation, and the inhibitory effect of DES was neutralised by anti-IGFBP-6 antibody. From the
immunohistochemical analysis of IGFBP-6 using biopsy samples from androgen-independent prostate cancer, we found IGFBP-6
expression in androgen independent prostate cancer, and that DES treatment increased the IGFBP-6 staining intensity of the cancer
cells in one sample. These findings suggested that DES induces IGFBP-6, which inhibits cell proliferation in an androgen-independent
prostate cancer cell line, PC-3. IGFBP-6 therefore might be involved in the direct effects of DES in androgen-independent prostate
cancer.
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Diethylstilbestrol (DES) is a synthetic oestrogen used in the
treatment of advanced human prostate cancer (Ferro et al, 1989),
and diethylstilbestrol diphosphate (DESdP) is a nontoxic prodrug
form of DES (Flocks et al, 1955; Abramson et al, 1982). The
palliative effects of DESdP administered to advanced-, hormone-
insensitive prostate cancer patients are well known (Flocks et al,
1955; Colapinto et al, 1961; Band et al, 1973; Droz et al, 1994;
Takezawa et al, 2001). DESdP relieves bone pain in the majority of
patients with metastatic prostate cancer who receive therapy
(Hawtrey et al, 1974; Takezawa et al, 2001).
The administration of oestrogenic analogues causes the
suppression of luteinising hormone-releasing-factor stimulation
of the pituitary gland (Paulson, 1984). In addition, the subsequent
reduction of testosterone synthesis induces anorchid levels of
circulating serum testosterone (Paulson, 1984). The beneficial
effect of DES therapy for previously orchiectomised patients,
however, indicates that DES may not operate solely through the
pituitary–gonadal axis. Several studies have sought to define the
mode of DES action on a cellular level. DES treatment inhibits
the growth of primary cultures derived from benign hyperplasia
and prostate carcinoma samples (Brehmer et al, 1972) as well as
prostate cancer cell lines (Schulz et al, 1990). Intracellular
localisation studies of DES inhibition have targeted mitochondrial
adenosine triphosphate synthase (McEnery et al, 1989), respiratory
chain enzymes (Schulz et al, 1990), and microtubules (Hartley
et al, 1985; Yokota et al, 1994) as sites of action. Robertson et al
(1996) reported that DES inhibits proliferation of androgen-
dependent and androgen-independent human prostate cancer cell
lines by promoting cell cycle arrest, inducing apoptosis through a
mechanism not mediated by estrogen receptors. However, the
direct effects of DES are unclear. The aim of this study was to
investigate the direct effects of DES in terms of gene expression,
and to characterise the biological significance of specific genes
involved in these effects.
MATERIALS AND METHODS
Cell and chemicals
The human prostate cancer cell lines LNCaP and PC-3 were
purchased from Dainippon Pharmaceutical (Tokyo, Japan) and
cultured in RPMI (Sigma, St Louis, MO, USA) supplemented with
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s10% fetal calf serum (FCS) (Moregate, Bulimba, Australia). DES
(Sigma) was dissolved in DMSO, and recombinant insulin-like
growth factor binding protein 6 (IGFBP-6) (Genzyme-techne,
Minnesota, USA) was resuspended with PBS and stored at  701C.
Neutralising goat anti-IGFBP-6-antibody (Genzyme-techne),
rabbit polyclonal anti-IGFBP-6-antibody (Austral biologicals, CA,
USA) and normal goat IgG (Genzyme-techne) were resuspended
with water and stored at  701C, and MTT was purchased from
Sigma and dissolved in water at 10mgml
 1.
Proliferation assay of human prostate cancer cells
Approximately 5 10
3 LNCaP cells per well or 1 10
4 PC-3 cells
per well were incubated with 100ml of culture medium (CM) for
24h at 371C in a 5% CO2 atmosphere. Thereafter, the CM was
aspirated and the cells were incubated with CM containing various
concentrations of DES, IGFBP-6, neutralising anti-IGFBP-6-anti-
body or normal goat IgG followed by a 4h pulse of 50mg of MTT
(Sigma). Isopropanol with 0.04 N hydrochloric acid (100ml) was
added to lyse the cells. Colour development at a wavelength of
540nM was measured by a Microplate Readers SOFTmax-J
enzyme-linked immumosorbent assay reader (Molecular Devices,
Sunnyvale, CA, USA).
DNA gel electrophoresis
LNCaP and PC-3 cells treated with various concentrations of DES
for 72h were harvested by trypsin treatment. Genomic DNA was
extracted using Wizard DNA extraction kit (Promega, Madison,
WI, USA). DNA pellets were resuspended in distilled water and
loaded in a 1.0% agarose gel. DNA was electrophoresed for 1.5h at
10Vcm
 1. Gels were stained with ethidium bromide (Sigma) and
visualised under UV light.
cDNA microarray analysis of the gene expression profiles
of LNCaP and PC-3 cells
cDNA microarray analysis of the gene expression profiles of
LNCaP and PC-3 cells were performed according to previously
described method (Suzuki et al, 2002). The cells were cultured in
CM with 50mM DES for 48h, after which total RNA was extracted
using an RNeasy Kit (Qiagen, Valencia, CA, USA) and treated with
DNase I (Invitrogen, Carlsbad, CA, USA). In total, 50mg of DNase I
treated total RNA was reverse-transcribed in the presence of 35mM
Cy3-dUTP or Cy5-dUTP (Amersham Pharmacia, Piscataway, NJ,
USA) and 10  lowT dNTP mix (5mM dATP, 5mM dGTP, 5mM
dCTP, 2mM dTTP) using an RNA Fluorescence Labelling Core Kit
(Takara, Tokyo, Japan). In total, 100pg of l polyAþRNA (Takara)
was added as a positive control. Unincorporated nucleotides and
salts were removed by chromatography with a Centrisep
(Princeton Separations, Adelphia, JN, USA). The Cy3 or Cy5
labelled cDNA after purification was mixed, and 30mg of human
Cot I DNA (Invitrogen), 16mg of poly-dA (Amersham Phamacia)
and 20mg of yeast tRNA (Sigma) were added to reduce nonspecific
binding. The probes were resuspended in 10ml of hybridisation
solution consisting of 6  SSC, 0.2% SDS and 5  Denhardt’s
solution (Invitrogen), and incubated at 981C for 2min and
then 41C for 10s. An IntelliGenet Human Cancer CHIP
Version 2.1 (Takara) glass slide was treated with prehybridisation
solution consisting of 6  SSC, 0.2% SDS, 5  Denhardt’s
solution and 1mgml
 1 denatured salmon sperm DNA
(Invitrogen). The denatured probe was placed onto the glass slide
with a coverslip, and hybridisation was performed at 651C for 15h.
The slides were then washed twice for 30min in 2  SSC at 551C,
5min in 2  SSC at 651C and 5min in 0.05  SSC at room
temperature.
The fluorescence intensities of the immobilised targets were
measured using an Affymetrix Array Scanner 418 (Affymetrix,
Santa Clara, CA, USA). The two fluorescent images (Cy3 and Cy5)
were separately scanned and the resulting imaging files were saved.
The fluorescence intensities were analysed using the imaging
software ImaGenet ver 3.0 (BioDiscovery, Los Angeles, CA, USA).
IntelliGenet Human Cancer CHIP ver 2.1 (Takara) carries 557
genes related to cancer (URL: http://www.takara.co.jp/ bio/goods/
new/new6/ new6-7.htm) and contains the following control spots:
housekeeping genes: beta-actin; Uba80 mRNA for ubiquitin;
phospholipase A2; glyceraldehydes-3-phosphate dehydrogenase
(GAPDH); tubulin, alpha2; major histocompatibility complex,
class I, A; ribosomal protein S5; general transcripton factor IIB;
hexokinase 1 F0; DNA from a non-human species: lambda-A,
lambda-B, lambda-C, lambda-D, lambda-E, pUC19, E.coli ompA,
E.coli ftsZ, Arabidopsis chlorophyll ab binding protein. The
normalisation constant from 76 spots of 12 housekeeping genes
was used to calculate the calibrated ratio for every cDNA spot
within the image. We then calculated the differential expression
ratios from two independent experiments and omitted spots for
which the fluorescence intensities of Cy3 and Cy5 were less than
2000.
Quantification of mRNA levels
Quantification of transcript levels was performed using a Light
Cycler (Roche Diagnostics,Indianapolis, IN, USA) according to the
manufacturer’s protocol and previous reports (ICJ, ACR). LNCaP
cells were cultured in CM with 50mM DES, and PC-3 cells were
culutured in CM with 12.5–50mM DES for 48h. Total RNA was
then extracted as described above and 2mg of this was reverse
transcribed using random primers (Invitrogen), according to the
manufacturer’s protocol. Amplification was performed in 18mlo f
QuantiTect SYBR Green PCR Master MIX (Qiagen) using 2mlo f
cDNA and forward and reverse primers. Next, PCR was performed
for one cycle of 15min at 951C followed by 50 cycles of 15s at 941C,
20s at 601C and 15s at 721C, with fluorescence detection being
carried out at 721C after each cycle. After the final cycle, melting-
point analysis of all samples and controls was performed from 65
to 951C. Absolute quantification of IGFBP-6 gene levels was
performed according to a previously described method (Suzuki
et al, 2002). For standard curve generation, PCR products of target
genes (known amounts) were used for template DNA, and for the
internal control 18s ribosomal RNA (rRNA) transcript levels were
used. Gene expression levels were expressed as fold changes of
those of the controls. The sequences of the primers for IGFBP-6
and 18s rRNA were as follows: IGFBP-6: forward, 50-AGG ATG
TGA ACC GCA GAG AC-30, reverse, 50-GGT AGA AGC CTC GAT
GGT CA-30; 18s rRNA: forward, 50-CGG CTA CCA CAT CCA AGG
AA-30, reverse, 50-GCT GGA ATT ACC GCG GCT GC-30.
Detection of IGFBP-6 protein by Western blotting
Detection of IGFBP-6 protein was performed according to
modification of a previously described method (Hasumi et al,
2003). Equal amounts of proteins (100mg) from PC-3 cells were
electrophoresed on a 5–20% SDS–polyacrylamide gel and
transferred onto a nitrocellulose membrane. After blocking, the
membrane was reacted with anti-IGFBP-6 antibody at a 1:500
dilution at room temperature for 1h. The membrane was then
reacted with horseradish peroxidase-linked rabbit immunoglobur-
in, and recombinant IGFBP-6 was visualised using an ECL
detection system (Amersham Biosciences, Tokyo, Japan). Data
were obtained from three experiments.
Immunohistochemical analysis of IGFBP-6 in clinical
tissues
To investigate the direct effects of DESdP, we examined androgen-
independent prostate cancer which initially responded favourably
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sto primary hormonal therapy, but then showed increases in
prostate-specific antigen (PSA) levels or clinical symptoms or new
lesions during treatment (Takezawa et al, 2001). Diethylstilbestrol
diphosphate (DESdP) at 250mgday
 1 was dissolved in 500ml of
physiological saline and intravenously infused for 28 days. PSA
levels were measured before and 28 days after DESdP administra-
tion was started by enzyme immunoassay (EIA) (TOSOH-II PA kit,
Tosoh Tokyo, Japan). Before and after DESdP administration, a
biopsy of the prostate was performed. Paraffin sections of 4-mm
thickness were cut from archival paraffin blocks containing
representative histology of the lesion. An immunohistochemical
study was then performed on the sections using the avidin-
biotinylated peroxidase complex (ABC) method with rabbit
polyclonal anti-IGFBP6 antibody (kindly provided by Dr J Martin,
University of Sydney, St Leonards, Australia) at 1:2000 dilution.
Briefly, paraffin sections were dewaxed with xylene and incubated
with 0.3% hydrogen peroxide in absolute methanol to block
endogenous peroxidase activity. Antigen-retrieval was then carried
out by autoclave-heating for 5min. To avoid nonspecific staining,
the sections were incubated with 10% normal goat serum for
30min at room temperature and were then treated with primary
antibodies at 41C overnight. After a thorough washing, the sections
were incubated with the secondary biotinylated anti-rabbit IgG
(Vector Laboratories, CA, USA) for 30min at room temperature
followed by the ABC complex (DakoCytomation Co. Ltd., Glostrup,
Denmark) for 30min at room temperature. Finally, the slides were
visualised with a solution containing 0.02% 3,30-diaminobenzidine
tetrahydrochloride and 0.005% H2O2, followed by light counter-
staining with haematoxylin.
RESULTS
DES induces apoptosis in prostate cancer cells, and so we first
performed a cell proliferation assay using MTT to examine the
effect of DES on prostate cancer cell proliferation. Viable cell
numbers of LNCaP and PC-3 cells were decreased after DES
administration in a dose-dependent manner as shown in Figure 1.
To confirm the occurrence of apoptosis, extracted genomic DNA
from LNCaP and PC-3 cells were electrophoresed. As shown in
Figure 2, DNA fragmentation was observed in both cells after DES
treatment; however, the extent of DNA fragmentation was low in
PC-3 cells in comparison with that in LNCaP cells.
To screen for the effect of DES on prostate cancer cells, changes
in gene expression in LNCaP and PC-3 cells was assessed using a
cDNA microarray. Two experiments showed that more than half of
the genes fixed on the slide glass were downregulated greater than
two-fold, and genes that were downregulated greater than five-fold
are shown in Table 1. Genes involved in cell attachment/invasion,
cell cycle, intracellular signalling, apoptosis and cell proliferation
are included. On the other hand, only four genes were upregulated
greater than two-fold after DES treatment as shown in Table 2.
IGFBP-6 and keratin 19 gene expression levels were upregulated
only in androgen-independent PC-3 cells. In clinical practice,
DES exerted its antitumour effect on androgen-independent
prostate cancer (Takezawa et al, 2001). Furthermore, IGFBP-6
inhibited the proliferation of rhabdomyosarcoma cells (Gallicchio
et al, 2001). These findings prompted us to study the effect
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Figure 1 Inhibition of the proliferation of human prostate cancer cell lines LNCaP and PC-3 by diethylstilbestrol (DES). Cells were incubated for 24h, and
thereafter CM was aspirated away and the cells were incubated with CM containing various concentrations of DES. After 72h, the number of viable cells was
measured by MTT assay. Optical densities (OD) of cell lysates were measured at a wavelength of 540nm. The values are expressed as meansþs.d. (n¼3),
and the P-values were o0.05 (*) and o0.01 (w).
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Figure 2 Gel electrophoresis of DNA of LNCaP and PC-3 treated with
diethylstilbestrol (DES). Cells treated with various concentrations of DES
for 72h were harvested, and DNA was extracted. DNA was electro-
phoresed in a 1.0% agarose gel. DNA fragmentation was observed after
DES treatment in both LNCaP (A) and PC-3 cells (B).
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sTo confirm the gene expression levels of IGFBP-6 in LNCaP and
PC-3 cells, quantitative real-time PCR was performed. Basal
expression levels of IGFBP-6 in LNCaP cells were about 20-fold
lower than those in PC-3 (data not shown). After incubation with
50mM DES for 48h, IGFBP-6 gene expression levels in LNCaP cells
showed no significant differences in comparison with the controls
(data not shown). In PC-3 cells, IGFBP-6 gene expression levels
significantly increased after DES treatment in a dose-dependent
manner as shown in Figure 3. Western blot analysis showed that
IGFBP-6 protein levels significantly increased in a dose-dependent
manner as shown in Figure 4.
We next studied the effect of recombinant IGFBP-6 on prostate
cancer cells. Although low-dose IGFBP-6 (62.5–125ngml
 1) did
not affect cell proliferation, high-dose IGFBP-6 (250–
1000ngml
 1) inhibited cell proliferation as shown in Figure 5.
After incubating the PC-3 cells with 800ngml
 1 recombinant
IGFBP-6, 20–30mgml
 1 anti-IGFBP-6 antibody neutralised the
inhibitory effects of cell proliferation. However, 5–10mgml
 1 anti-
IGFBP-6 antibody did not significantly neutralise this effect
(Figure 6). Finally, we examined the effect of neutralising anti-
IGFBP-6 antibody on DES treated PC-3 cells. Low-dose antibody
(10mgml
 1) did not show a significant effect on cell proliferation,
Table 1 Gene List: reduced after DES treatment
Category GenBank Acc. No. Gene name LNCaP PC-3
Cell attachment/cell invasion U41766 A disintegrin and metalloproteinase domain 9 KK
Z13009 Cadherin 1 (E-cadherin) K
D21255 Cadherin 11 (osteoblast) K
X87838 Catenin, beta 1 KK
M14648 Integrin, alpha V K
Cell cycle X05360 Cell division cycle 2 KK
S72008 Cell division cycle 10 KK
X51688 Cyclin A2 K
M74091 Cyclin C KK
X77784 Cyclin G1 KK
U47414 Cyclin G2 KK
X17644 G1 to G2 phase transition 1 KK
Intracellular signalling AL035071 MAP kinase 1 KK
X80692 MAP kinase 6 KK
L35263 MAP kinase 14 KK
L11284 MAPK kinase 1 KK
M97935 STAT-1, 91kDa KK
Apoptosis U37547 Apoptosis inhibitor 1 KK
NM012103 Apoptosis inhibitor 2 KK
NM013979 BCL2/adenovirus E1B 19kDa interacting protein 3 KK
U13737 Caspase 3 KK
Others J04088 Topoisomerase (DNA) II, alpha KK
M15796 PCNA K
K indicates that the gene expression level was reduced more than five-fold after DES treatment.
Table 2 Gene list: elevated after DES treatment
GenBank
Acc. No. Gene name LNCaP PC-3
D86962 Growth factor receptor-bound protein 10 K
X57351 IFN induced transmembrane protein 2 K
NM002178 Insulin like growth factor binding protein-6 K
Y00503 Keratin 19 K



























































Figure 3 Insulin-like growth factor binding protein-6 (IGFBP-6) gene
expression levels in PC-3 cells. Transcript levels were measured by
quantitative real-time PCR after treatment with various concentrations of
DES. 18s ribosomal RNA transcript levels were used for the internal
control, and gene expression levels were expressed as fold changes relative
to those of the controls. IGFBP-6 gene expression was significantly
increased after DES treatment in a dose-dependent manner in PC-3 cells.
The values are expressed as meansþs.d. (n¼3), and the P-values were
o0.05 (*) and o0.01 (w).
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sbut, cell proliferation was significantly upregulated with incuba-
tion with high-dose antibody (30mgml
 1) as shown in Figure 7.
Normal goat IgG did not affect on cell proliferation, as shown in
Figures 6 and 7.
Clinically, DESdP treatment decreased PSA levels in all patients
(Takezawa et al, 2001). In the prostate biopsy tissues before and
after DES-dP treatment, cancer cells were detected in four patients.
IGFBP-6 expression was examined by immunohistochemical
staining, and was visible in the cytoplasm of cancer cells in the
organ. Before treatment with DESdP, IGFBP-6 expression was
positive in three patients. In one of them (patient #1), IGFBP-6
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Figure 4 Insulin-like growth factor binding protein-6 (IGFBP-6) protein
levels in PC-3 cells. Protein levels were measured by Western blot analysis
after treatment with various concentrations of DES. Proteins levels were
expressed as fold changes. IGFBP-6 protein expression was significantly
increased after DES treatment in a dose-dependent manner in PC-3 cells.
The values were expressed as meansþs.d. (n¼3), and the P-values were
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Figure 5 Inhibition of proliferation of human prostate cancer PC-3 cells
by recombinant IGFBP-6. Cells were incubated for 24h, and thereafter CM
was aspirated away and the cells were incubated with CM containing
various concentrations of IGFBP-6. After 48h, the viable cell number was
measured by MTT assay. The optical density (OD) of the cell lysates is
expressed as the fold change. Recombinant IGFBP-6 inhibited the
proliferation of PC-3 cells in a dose-dependent manner. The values are
expressed as meansþs.d. (n¼3), and the P-values were o0.05 (*).
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Figure 6 Effects of IGFBP-6 and anti-IGFBP-6 antibody on PC-3 cell
proliferation. Cells were incubated for 24h, and thereafter CM was
aspirated away. After 48h of incubation of PC-3 cells with 800ngml
 1
recombinant IGFBP-6 and various concentrations of anti-IGFBP-6 or
normal goat IgG, the viable cell number was measured by MTT assay. The
optical density (OD) of the cell lysates was expressed as the fold change. In
total, 20–30mgml
 1 of anti-IGFBP-6 antibody significantly neutralised the
inhibitory effects of cell proliferation. The values are expressed as
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Figure 7 Effect of neutralising anti-IGFBP-6 antibody on DES-treated
PC-3 cells. Cells were incubated for 24h, and thereafter CM was aspirated
away. After 48h incubation of PC-3 cells with 6.25mM DES and various
concentrations of anti-IGFBP-6 antibody or normal goat IgG, the viable cell
number was measured by MTT assay. The optical density (OD) of the cell
lysates was expressed as the fold change. Cell proliferation was significantly
upregulated by incubation with high-dose antibody (30mgml
 1). Anti-
IGFBP-6 antibody inhibited DES-induced cell growth suppression. The
values are expressed as meansþs.d. (n¼3), and the P-values were o0.01
(w).
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s(patients #2 and #7) it was not changed (Table 3). DESdP treatment
increased the IGFBP-6 staining intensity in cancer cells of patient
#1 as shown in Figure 8.
DISCUSSION
We first confirmed the antiproliferative and apoptosis-inducing
effects of DES on prostate cancer cells. Cell proliferation of LNCaP
or PC-3 cells was inhibited by DES in a dose-dependent manner in
combination with cellular apoptosis. This is consistent with results
reported by Robertson et al (1996), who examined the induction of
apoptosis by DES in PC-3 cells. They concluded that the direct
cytotoxic effects of DES in prostate cancer cells are estrogen
receptor-independent and involve the promotion of cell cycle
arrest and apoptosis.
Recently, gene expression profiles can be screened using a cDNA
microarray, which provides important information on biological
activities. We previously reported the gene expression profiles of
LNCaP and PC-3 cells treated by genistein using a cDNA
microarray, and found unique genes involved in the direct effects
of genistein on prostate cancer cells (Suzuki et al, 2002). The
present study showed that expression levels were downregulated
for most genes. This downregulation reflects the suppressive
effects of DES. However, the expression of IGFBP-6 and keratin 19
gene were upregulated in androgen-independent prostate cancer
PC-3 cells. IGFBP-6 inhibits the proliferation of rhabdomyosarco-
ma cell lines (Gallicchio et al, 2001). Therefore, we characterised
the biological action of IGFBP-6 in PC-3 cells. In rhabdomyosar-
coma cells, IGFBP-6 inhibited cell proliferation in a dose-
dependent manner by inhibiting insulin-like growth factor II
(IGF-II), which stimulates cell proliferation. Gallicchio et al
concluded that IGFBP-6 exerts an inhibitory effect on the
proliferation and survival of rhabdomyosarcoma cells in vitro.I n
the present study, the proliferation of PC-3 cells was inhibited by
recombinant IGFBP-6 in a dose-dependent manner. We also found
that DES administration induces IGFBP-6 at the mRNA and
protein level. Furthermore, anti-IGFBP-6 antibody antagonises the
inhibitory effect of DES. Therefore, we speculate that IGFBP-6 is
involved in the direct effect of DES.
IGFBP-6 is unique for its dramatically higher affinity for IGF-II
(Bach et al, 1999), and is an inhibitor of IGF-II (Kiefer et al, 1992;
Bach et al, 1994; Bach et al, 1999). IGF-II is an autocrine growth
factor that affects neuroblastoma (Grellier et al, 2002) and
rhabdomyosarcoma (Gallicchio et al, 2001) cells. In vivo, Grellier
et al reported on the transplantation of human IGFBP-6-
expressing neuroblastoma cells in nude mice, and their results
showed a lower incidence of xenografts, which also exhibited
slower growth than those obtained using control cells (1998). IGF-
II was more strongly expressed in control tumours in this model.
They concluded that excess IGFBP-6 displaces IGF-II from IGFBP-
2, thus preventing it from potentiating the mitogenic action of IGF-
II (2002). Gallicchio et al (2001) also reported that IGFBP-6
dramatically inhibits xenograft growth of rhabdomyosarcoma
cells.
In prostate cancer, Kimura reported that IGF-II occurred at the





Figure 8 Immunohistochemical staining of IGFBP-6. IGFBP-6 was visible
in the cytoplasm of cancer cells in the organ (A). For one patient, DESdP
treatment increased the IGFBP-6 staining intensity in cancer cells (B). The
immunostained section in (B) is from the same patient as that shown in
(A). Cells that stained positively for IGFBP-6 are brown in colour.
Table 3 Clinical and immunohistchemical data of androgen-independent prostate cancer patients
Immunohistochemical analysis of IGFBP6 in prostate biopsy tissues PSA (ngdl
 1)
Patient Pathology at diagnosis Before DES-dP treatment After DES-dP treatment Before After
1 Poorly diff. Positive More positive 821 238
2 Moderately diff. Positive Positive 417 194
3 Moderately diff. No cancer cells No cancer cells 25.3 9.3
4 Moderately diff. No cancer cells No cancer cells 166 112
5 Poorly diff. No cancer cells No cancer cells 35.6 2.4
6 Poorly diff. Negative Negative 641 261
7 Poorly diff. Positive Positive 305 23.6
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ssignificant amounts of IGF-I protein in the conditioned media of
these cell-lines. Furthermore, IGF-II stimulates the growth of PC-3
cells. Therefore, the autocrine activity of IGF-II may contribute in
part to the proliferation of PC-3 cells (Kimura et al, 1996).
Drivdahl reported that the upregulation of IGFBP-6 occurs in
association with the activity of 1,25-dihydroxyvitamin D3 in
prostate cancer cells, and suggested a role for IGFBP-6 in the
suppression of prostate tumour cell growth (Drivdahl et al, 1995).
This prompted us to investigate the effect of IGFBP-6 on androgen-
independent prostate cancer PC-3 cells. The present findings are
the first observations to confirm the inhibitory effect of IGFBP-6
on PC-3 cells.
In clinical practice, we treated seven patients with androgen-
independent prostate cancer with DESdP (Table 3). PSA levels
decreased in all patients, and palliative effects were obtained.
Viable cancer cells were confirmed by prostate needle biopsy
specimens for four patients. Three of the four were positive for
IGFBP-6 staining. For one patient, IGFBP-6 immunostaining was
upregulated as shown in Figure 8. This suggests that upregulation
of IGFBP-6 was observed in a part of patients with androgen-
independent prostate cancer treated by DESdP. We considered that
the heterogeneity of biological features of prostate cancer may
have affected the present results.
In conclusion, we found that many genes including cell
attachment/invasion, cell cycle, intracellular signalling, apoptosis
and cell proliferation genes, are downregulated after DES
treatment in human prostate cancer LNCaP and PC-3 cells.
However, IGFBP-6 is upregulated at the mRNA and protein level in
androgen-independent human prostate cancer PC-3 cells. rIGFBP-
6 inhibits PC-3 cell proliferation, and neutralising anti-IGFBP-6
antibody antagonises the inhibitory effect of DES in PC-3
cells. These finding suggest that IGFBP-6 might be involved in
the direct effect of DES in androgen-independent human prostate
cancer.
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